Better Terminology, Not Better Models — Pharma's AI Bottleneck in Real-World Data Analysis
CONCEPTOverview A MedCity News opinion piece argues that the primary bottleneck in AI-enabled real-world data analysis for pharma is not computational power, model architecture, or training data volume — it is the semantic layer: the precise clinical meaning that AI must reason over. Better terminology infrastructure, not better models, is the key to unlocking pharma AI's potential. The Semantic Layer Problem AI models applied to real-world clinical data must interpret terms that carry precise medical meaning — drug names, diagnosis codes, procedure descriptions, lab values — in contexts where synonymy, ambiguity, and institutional variation are pervasive. Without a robust semantic layer (standardized terminologies, ontologies, and mapping infrastructure), even powerful models reason over imprecise inputs and produce unreliable outputs. Why Better Models Alone Won't Fix It The piece challenges the assumption that scaling model size or improving architecture will resolve real-world data analysis problems. The bottleneck is upstream: if the semantic representation of clinical concepts is ambiguous or inconsistent, larger models will be better at being confidently wrong. Solving the terminology problem requires investment in ontology engineering, data curation, and standards alignment — not just model training. Implications for Pharma AI Strategy Pharmaceutical companies investing heavily in AI for pharmacovigilance, real-world evidence generation, and drug development should…
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.